Translating Research Into Practice

The Long and Short of Tamoxifen Therapy: A Review of the ATLAS Trial

G. Lita Smith, MS, RN, ACNP

From University of Michigan, Ann Arbor, Michigan

Author's disclosures of potential conflicts of interest are found at the end of this article.

Correspondence to: G. Lita Smith, MS, RN, ACNP, University of Michigan, Breast Oncology, 1500 East Medical Center Drive, Ann Arbor, MI 48109. E-mail: glorials@umich.edu


J Adv Pract Oncol 2014;5:57-60# | DOI: 10.6004/jadpro.2014.5.1.5 | © 2014 Harborside Press®


  

ABSTRACT

Review of “Long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial” by Davies et al. (2013), Lancet, 381, 805–816. For another perspective on the ATLAS trial, please see the article on randomization and adjusting for covariates by Dustin Dickerson starting on page 61.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.